HLTF Recombinant Monoclonal Antibody

Overview

This is a monoclonal anti-HLTF antibody raised in Rabbit, with confirmed utility in ELISA, WB, IHC, FC. It is designed to detect HLTF protein in Human and supports researchers working in others contexts.

Key elements and design rationale

• Immunogen: A synthesized peptide from human HLTF protein — determines the epitope region; confirm compatibility with sample preparation and expected post-translational modifications.
• Host species (Rabbit): Requires anti-rabbit-IgG secondary reagents for indirect detection.
• Monoclonal format: Single-epitope binding provides high specificity and lot-to-lot reproducibility. Confirm epitope accessibility under your assay conditions.
• Isotype (IgG): Matched secondary antibodies and isotype controls required. Compatible with standard Protein A/G purification workflows.
• Purification (Affinity chromatography): Enriches for specific immunoglobulin classes; reduces non-specific background vs. crude antisera.

Biological background

HLTF (also referred to as DNA-binding protein/plasminogen activator inhibitor 1 regulator antibody, Helicase like transcription factor antibody, Helicase-like transcription factor antibody, HIP116 antibody, HIP116A antibody, HLTF 1 antibody, Hltf antibody, HLTF_HUMAN antibody, HLTF1 antibody, p113 antibody, RING finger protein 80 antibody, RNF80 antibody, SMARC A3 antibody, SMARCA 3 antibody, SMARCA3 antibody, SNF2-like 3 antibody, SNF2L3 antibody, Sucrose nonfermenting protein 2 like 3 antibody, Sucrose nonfermenting protein 2-like 3 antibody, SWI/SNF related matrix associated actin dependent regulator of chromatin subfamily A member 3 antibody, SWI/SNF-related matrix-associated actin-dependent regulator of chromatin a3 antibody, SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily A member 3 antibody, ZBU 1 antibody, ZBU1 antibody) is a protein target studied in Human systems. Expression, subcellular localization, and post-translational modifications vary across cell types and disease states — factors critical to antibody-based detection design. Consult UniProt, NCBI Gene, and primary literature for current annotation of HLTF biology in others.

Common research applications

• ELISA: Quantification of soluble target in biological fluids or culture supernatants. Ensure samples are within the linear detection range.
• WB: Confirms target molecular weight and distinguishes isoforms under denaturing conditions.
• IHC: Visualization of target in FFPE or frozen tissue sections. Optimize antigen retrieval and secondary detection for each tissue type.
• FC: Applicable for FC-based detection; refer to product documentation for optimized conditions.

Notes for experimental interpretation

• Isotype controls: Use an isotype-matched (IgG from Rabbit) control at equivalent concentration to assess non-specific background.
• Cross-reactivity: Confirm the clone does not cross-react with related family members under your assay conditions.
• Matrix effects: Sample matrix can affect performance; pilot dilution linearity and spike-recovery experiments are advised for quantitative studies.
• Species reactivity: Confirmed for Human. Extrapolation to untested species requires empirical validation.

This product is a recombinant monoclonal antibody expressed in HEK293F cells.

• Datasheet (12946141)

Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.